Rupatadine
From Wikipedia, the free encyclopedia
 |
|
|
Rupatadine
|
|
| Systematic (IUPAC) name | |
| 8-chloro-6,11-dihydro-11-(1-((5-methyl-3-pyridyl)methyl)- 4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine |
|
| Identifiers | |
| CAS number | |
| ATC code | R06 |
| PubChem | |
| Chemical data | |
| Formula | C26H26ClN3 |
| Mol. mass | 415.958 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 99% |
| Metabolism | Hepatic, CYP-mediated |
| Half life | 5.9 hours |
| Excretion | Fecal (60.9%) and renal (34.6%) |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Rupatadine is a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. Ruptatadine is marketed by Panacea-Biotech under the trade name Ralif. Ralif is approved for the treatment of allergic rhinitis. Useful for allergic urticaria.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||||
